FDA Moves to Tighten Rare-Disease Drug Reviews as New Leadership Seeks Consistency
The U.S. Food and Drug Administration is advancing a new rare-disease framework that could reshape how experimental treatments are designed, reviewed and approved. The initiative signals a shift toward greater consistency and broader evidentiary standards, a move that may raise the bar for developers while potentially improving regulatory predictability.
